Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ADDERALL XR 15 vs ADDERALL 5
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
ADDERALL XR contains a mixture of amphetamine salts, including dextroamphetamine and levoamphetamine. The mechanism of action involves increasing synaptic levels of dopamine and norepinephrine by inhibiting their reuptake and enhancing their release from presynaptic terminals, leading to CNS stimulation.
Adderall 5 is a combination of dextroamphetamine and amphetamine, which are central nervous system stimulants. They increase the levels of dopamine and norepinephrine in the synaptic cleft by inhibiting their reuptake and promoting their release from presynaptic neurons.
Attention Deficit Hyperactivity Disorder (ADHD),Narcolepsy (off-label)
Attention Deficit Hyperactivity Disorder (ADHD),Narcolepsy
Oral, 20-60 mg once daily in the morning; initial dose 20 mg once daily, titrated by 10-20 mg weekly based on tolerability and efficacy.
Initial: 5 mg orally once or twice daily; increase by 5 mg increments at weekly intervals. Maximum: 40 mg/day in divided doses.
The terminal elimination half-life of amphetamine in adults is approximately 10-13 hours; in children, it is slightly shorter (6-8 hours). For the l-amphetamine isomer, the half-life is 9-11 hours. The extended-release formulation provides a prolonged duration of effect due to a biphasic release profile.
Immediate-release: 9–11 hours (mean 10 hours for dextroamphetamine); extended-release: 10–13 hours. Terminal half-life may be prolonged with urinary p H >7.
Amphetamine is primarily metabolized in the liver via cytochrome P450 enzymes, including CYP2D6, to various oxidative and deaminated metabolites. Aromatic hydroxylation produces p-hydroxyamphetamine and p-hydroxynorephedrine. Some metabolism also occurs via monoamine oxidase (MAO).
Amphetamine is metabolized via CYP2D6, with deamination and oxidation as major pathways.
Renal: approximately 90% of a dose is excreted in urine, with about 30% as unchanged amphetamine and the remainder as metabolites including deaminated and oxidized products; fecal excretion accounts for less than 10%.
Renal (90% as unchanged drug and metabolites; ~30% unchanged), minor fecal elimination (<5%).
Amphetamine is approximately 20% bound to plasma proteins, primarily albumin.
~16% bound to plasma proteins (primarily albumin).
Volume of distribution for amphetamine is about 3-4 L/kg, indicating extensive tissue distribution. The large Vd contributes to the long terminal half-life.
3.5–4.5 L/kg; indicates extensive tissue distribution (e.g., brain, lungs).
Oral bioavailability of amphetamine from ADDERALL XR is approximately 90-100% relative to an oral solution; the extended-release formulation has a bioavailability similar to immediate-release tablets when administered orally.
Oral immediate-release: 96–100% (first-pass metabolism minimal); extended-release: approximately 96% relative to immediate-release.
GFR 15-30 m L/min: reduce dose by 50%; GFR <15 m L/min: use with caution, maximum dose 30 mg daily; hemodialysis: not recommended.
GFR 15-29 m L/min: reduce dose by 50%; GFR <15 m L/min: use maximum of 50% of usual dose; not recommended in ESRD.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: not recommended.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: avoid use.
Children 6-12 years: initial 10 mg once daily, increase by 5-10 mg weekly up to 30 mg/day; adolescents 13-17 years: initial 10 mg once daily, increase by 10 mg weekly up to 40 mg/day.
Children 3-5 years: initial 2.5 mg daily, increase by 2.5 mg weekly; max 40 mg/day. Children ≥6 years: initial 5 mg once or twice daily, increase by 5 mg weekly; max 40 mg/day (or 20 mg/day for extended-release).
Start at 10 mg once daily, increase slowly by 5-10 mg every 2 weeks; monitor cardiovascular status and cognitive function; consider lower maintenance doses (20-30 mg daily) due to increased sensitivity.
Initiate at 2.5 mg once or twice daily; increase by 2.5-5 mg weekly; monitor for cardiovascular effects and confusion.
WARNING: ABUSE, MISUSE, AND ADDICTION. ADDERALL XR has a high potential for abuse, which can lead to tolerance, dependence, and serious cardiovascular or psychiatric adverse events. Misuse may cause sudden death or serious cardiovascular events.
Adderall has a high potential for abuse and dependence. Misuse may cause sudden death or serious cardiovascular events.
Serious cardiovascular events including sudden death, stroke, and myocardial infarction have been reported in patients with pre-existing structural cardiac abnormalities or other serious heart problems.,Blood pressure and heart rate should be monitored, increased risk of hypertension and tachycardia.,May exacerbate psychiatric disorders including pre-existing psychosis, mania, or bipolar disorder; emergence of new psychotic or manic symptoms.,Long-term suppression of growth in children; monitor growth during treatment.,Risk of serotonin syndrome when co-administered with serotonergic drugs.,Risk of seizures in patients with a history of seizures.,Visual disturbances including difficulty with accommodation and blurred vision.
Serious cardiovascular events including sudden death in patients with pre-existing structural cardiac abnormalities,Blood pressure and heart rate increases,Psychiatric adverse events such as psychosis or mania,Growth suppression in pediatric patients,Seizures,Peripheral vasculopathy including Raynaud's phenomenon,Serotonin syndrome when co-administered with serotonergic drugs
Hypersensitivity to amphetamine products or any component of the formulation,Concurrent use or within 14 days of monoamine oxidase inhibitors (MAOIs) due to risk of hypertensive crisis,Advanced arteriosclerosis,Symptomatic cardiovascular disease,Moderate to severe hypertension,Hyperthyroidism,Glaucoma,Agitated states,History of drug abuse
Advanced arteriosclerosis,Symptomatic cardiovascular disease,Moderate to severe hypertension,Hyperthyroidism,Glaucoma,Agitated states,History of drug abuse,Concurrent use of MAOIs or within 14 days of discontinuing MAOI,Hypersensitivity to amphetamine products
Avoid high-fat meals as they delay absorption and reduce peak concentration. Avoid acidic foods (e.g., citrus fruits, cola, vinegar) close to dosing, as they may decrease absorption. Do not consume alcohol while taking Adderall XR.
Avoid acidic foods or vitamin C supplements within 1 hour of dosing as they decrease absorption. Grapefruit may increase drug levels. Caffeine and other stimulants should be limited. Avoid alcohol. High-fat meals may delay onset but not overall absorption.
Pregnancy Category C. First trimester: Possible increased risk of congenital malformations (cardiac, orofacial clefts) based on limited human data; amphetamines shown to cause developmental toxicity in animal studies. Second/third trimester: Risk of premature delivery, low birth weight, neonatal withdrawal syndrome (irritability, feeding difficulties).
Pregnancy Category C (pre-2015) / Not assigned under current FDA labeling. First trimester: Studies suggest a possible small increased risk of congenital malformations, particularly cardiovascular defects and oral clefts, but absolute risk is low. Second and third trimesters: Exposure may increase risk of preterm delivery, low birth weight, and neonatal withdrawal symptoms including irritability, dysphoria, and feeding difficulties. Chronic use may lead to fetal growth restriction.
Excreted into breast milk; M/P ratio approximately 2.6-7.5 for dextroamphetamine. Not recommended due to potential for adverse effects on infant (insomnia, irritability, feeding problems, weight loss). American Academy of Pediatrics considers use compatible with caution, but alternative treatments preferred.
Amphetamine is excreted into human breast milk. The milk-to-plasma (M/P) ratio is approximately 2.0–3.0. Relative infant dose is estimated at 5–10% of the maternal weight-adjusted dose. Use while breastfeeding is generally not recommended due to potential adverse effects on the infant, including irritability, poor feeding, and insomnia. Consider alternative treatments or discontinue breastfeeding.
Pregnancy may increase clearance of amphetamines (e.g., 30-50% increase due to enhanced hepatic metabolism and renal blood flow), potentially requiring dose adjustments. However, avoid use during pregnancy unless benefit outweighs risk; if necessary, monitor clinical response and consider dose increase based on efficacy/toxicity.
Pharmacokinetic changes in pregnancy (increased volume of distribution, enhanced hepatic metabolism, and increased renal clearance) can lower amphetamine plasma concentrations. Dose adjustments may be necessary to maintain therapeutic effect; however, formal guidelines are lacking. Use the lowest effective dose and monitor clinical response. Avoid during pregnancy unless potential benefits outweigh risks.
Adderall XR 15 is a once-daily extended-release formulation of amphetamine salts. Monitor for cardiovascular events; check blood pressure and heart rate at baseline and periodically. Avoid use in patients with structural cardiac abnormalities, cardiomyopathy, or serious arrhythmias. Use with caution in patients with a history of substance abuse. Do not crush or chew capsules; sprinkle contents on applesauce if needed. Onset of action is 1-2 hours with duration of 10-12 hours.
ADDERALL 5 (amphetamine/dextroamphetamine) is a CNS stimulant. Note that 5 mg is a low starting dose; titrate based on response and tolerability. Avoid use in patients with structural cardiac abnormalities, glaucoma, hyperthyroidism, or history of drug abuse. Monitor for hypertension, tachycardia, and psychiatric symptoms. Can worsen tics or Tourette syndrome. Use with caution with MAOIs (risk of hypertensive crisis).
Take exactly as prescribed; do not increase dose without consulting your doctor.,Swallow capsule whole; do not crush or chew. If needed, open capsule and sprinkle contents on a spoonful of applesauce, swallow immediately without chewing.,Avoid taking late in the day to prevent insomnia.,Common side effects include decreased appetite, trouble sleeping, dry mouth, and headache.,This drug has a high potential for abuse and dependence; keep in a safe place.,Report any signs of heart problems: chest pain, shortness of breath, fainting.,Monitor growth in children; height and weight should be checked during treatment.
Take exactly as prescribed; do not increase dose without consulting doctor.,Swallow tablet whole; do not crush or chew.,Avoid taking late in the day to prevent insomnia.,May cause dizziness; avoid driving if affected.,Report chest pain, shortness of breath, or fainting.,May be habit-forming; do not share with others.,Store at room temperature away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ADDERALL XR 15 vs ADDERALL 5, answered by our medical review team.
ADDERALL XR 15 is a CNS Stimulant that works by ADDERALL XR contains a mixture of amphetamine salts, including dextroamphetamine and levoamphetamine. The mechanism of action involves increasing synaptic levels of dopamine and norepinephrine by inhibiting their reuptake and enhancing their release from presynaptic terminals, leading to CNS stimulation.. ADDERALL 5 is a CNS Stimulant that works by Adderall 5 is a combination of dextroamphetamine and amphetamine, which are central nervous system stimulants. They increase the levels of dopamine and norepinephrine in the synaptic cleft by inhibiting their reuptake and promoting their release from presynaptic neurons.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ADDERALL XR 15 and ADDERALL 5 depend on the specific clinical indication. These are both CNS Stimulant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ADDERALL XR 15 is: Oral, 20-60 mg once daily in the morning; initial dose 20 mg once daily, titrated by 10-20 mg weekly based on tolerability and efficacy.. The standard adult dose of ADDERALL 5 is: Initial: 5 mg orally once or twice daily; increase by 5 mg increments at weekly intervals. Maximum: 40 mg/day in divided doses.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ADDERALL XR 15 and ADDERALL 5 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ADDERALL XR 15 is classified as Category C. Pregnancy Category C. First trimester: Possible increased risk of congenital malformations (cardiac, orofacial clefts) based on limited human data; amphetamines shown to cause deve. ADDERALL 5 is classified as Category C. Pregnancy Category C (pre-2015) / Not assigned under current FDA labeling. First trimester: Studies suggest a possible small increased risk of congenital malformations, particularl. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.